Core Insights - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceutical sectors [1] - The company emphasizes a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [1] - Allka Research is committed to simplifying investment strategies, making them accessible to both seasoned and novice investors [1] Company Mission - The mission of Allka Research is to empower individuals financially by sharing knowledge and insights through platforms like Seeking Alpha [1] - The company aims to demystify investing, fostering a community of informed investors capable of navigating the markets intelligently [1] - Allka Research seeks to contribute thought-provoking analyses and informed perspectives to enhance the investment experience for its audience [1]

Core Insights - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceutical sectors [1] - The company emphasizes a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [1] - Allka Research is committed to simplifying investment strategies, making them accessible for both seasoned and novice investors [1] Company Mission - The mission of Allka Research is to empower individuals financially by sharing knowledge and insights through the Seeking Alpha platform [1] - The company aims to provide thought-provoking analyses and informed perspectives to foster a community of informed investors [1] - Allka Research seeks to demystify investing, inspiring confidence in readers to navigate the financial markets intelligently [1]

Core Insights - Gilead is focusing on its growth story for 2026 and beyond, emphasizing the importance of its recent developments and pipeline [2][3] - The launch of lenacapavir in 2025 was a significant milestone for Gilead, highlighting its commitment to addressing the global HIV epidemic [3] - Gilead's commercial growth has been robust, with a strong and diverse pipeline, marking a significant period of launch activity [4] Company Highlights - Gilead's pipeline is described as the strongest and most diverse in its nearly 40-year history, indicating a promising future for the company [4] - The company distinguishes itself from other big pharma firms by not facing any major loss of exclusivity (LOE) issues, which positions it favorably in the market [4]

Summary of Gilead's Conference Call Company Overview - **Company**: Gilead Sciences - **Industry**: Biotechnology and Pharmaceuticals Key Points 1. Growth and Pipeline - Gilead's growth story is highlighted for 2026 and beyond, with a strong focus on the HIV business and the launch of Lenacapavir, which is crucial for ending the HIV epidemic globally [2][4] - The company has the strongest and most diverse pipeline in its nearly 40-year history, with significant launch activities expected [2][5] - Gilead has no major loss of exclusivity (LOE) for another decade, providing a stable backdrop for growth [3] 2. HIV Business - The HIV revenue growth was reported at 7% through Q3 of the previous year, despite a $900 million headwind from Part D [6] - Gilead plans to launch up to seven HIV prevention and treatment products by the end of 2033, with Biktarvy remaining the standard of care [7][14] - The company is investing in Biktarvy and Lenacapavir, with an FDA decision for a daily oral combination expected in the second half of the year [8][19] 3. Prevention Market - Gilead is the market leader in PrEP (pre-exposure prophylaxis) and has achieved a revenue target of $150 million for the Yes To Go product in 2025 [10][11] - The PrEP market is larger than official estimates, with significant growth potential [11] - Lenacapavir was launched in sub-Saharan Africa, marking a significant milestone in Gilead's efforts to combat HIV globally [13] 4. Treatment Pipeline - Gilead is preparing for the launch of Trodelvy in the first-line setting for triple-negative breast cancer, which could double patient opportunities [16] - Anito-cel, targeting fourth-line multiple myeloma, is expected to launch in the second half of the year, with a strong safety profile [17][45] - The company is confident in its treatment pipeline, with multiple options for patients, including daily, weekly, and monthly therapies [38][41] 5. Financial Management - Gilead has maintained strong financial discipline, with operating margins in the top quartile of peers and a commitment to returning at least 50% of free cash flow to shareholders [23][25] - Since 2020, Gilead has distributed over $22 billion in dividends, with a 16% growth in dividends during that period [24] - The company is actively pursuing bolt-on acquisitions to enhance its portfolio and financial performance [26][55] 6. Regulatory and Market Position - Gilead is focused on addressing affordability issues in the U.S. healthcare system and is engaged in dialogue with the administration regarding pricing and access [59][60] - The company has a robust plan for managing the MFN (Most Favored Nation) agreements, viewing them as manageable for future operations [59][60] 7. Future Expectations - Gilead anticipates continued growth in its base business, with a projected 7% to 8% growth in 2023 and 2024 [25] - The company is committed to maintaining a strong pipeline and optimizing its operations to support long-term shareholder value [27][52] Additional Insights - Gilead's commitment to innovation and addressing unmet medical needs is evident in its diverse pipeline and proactive approach to market challenges [15][26] - The company emphasizes the importance of having multiple treatment options available to cater to different patient needs and preferences [41][44]

Gilead in 2026 J . P. M o r g a n H e a l t h c a r e C o n f e r e n c e 1 2 J a n u a r y 2 0 2 6 Forward-Looking Statements Statements included in this document that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relati ...

Core Insights - OncoNano Medicine, Inc. has announced a research collaboration with Gilead Sciences, Inc. to evaluate OncoNano's ON-BOARD encapsulation technology with Gilead's drug candidate [1] Group 1: Collaboration Details - The collaboration aims to assess the stability, selectivity, and efficacy of Gilead's drug candidate when encapsulated using OncoNano's ON-BOARD technology [1] - This partnership highlights the broad applicability of OncoNano's technology in enhancing drug delivery systems [1]

Group 1 - Bernstein SocGen Group reiterated its Outperform rating and $135 price target on Gilead Sciences, citing limited financial exposure to recent Medicaid pricing developments [1] - Only certain products, representing about 60% of Gilead's portfolio, were aligning with MFN pricing for Medicaid, specifically Genvoya and Odefsey, which together generated approximately $750 million in Medicaid gross spend in 2023 [2] - Concerns around Medicaid pricing risk for Biktarvy were alleviated, with negotiations resulting in a favorable outcome, and the estimated 2026 revenue impact for Genvoya and Odefsey combined is expected to be minimal, less than $200 million, and in the low single-digit percentage range for the overall company [3]

Core Insights - Royalty Pharma has acquired the final portion of PTC Therapeutics' royalty on Roche's Evrysdi for $240 million upfront and up to $60 million in sales-based milestones [1] Group 1: Transaction Details - Royalty Pharma will own 100% of the tiered royalty structure ranging from 8% to 16% on worldwide net sales of Evrysdi [3] - The royalty rates are structured as follows: 8% on sales up to $500 million, 11% on sales between $500 million and $1 billion, 14% on sales between $1 billion and $2 billion, and 16% on sales over $2 billion [3] - Royalty Pharma will start receiving the increased royalty rates in Q1 2026 based on Evrysdi sales in Q4 2025 [3] Group 2: Product Information - Evrysdi is an orally administered SMN2 splicing modifier for treating spinal muscular atrophy, approved by the FDA in 2020 [2] - The product has treated over 21,000 patients globally and generated sales of approximately CHF 1.6 billion ($1.9 billion) in 2024, reflecting an 18% year-over-year growth at constant exchange rates [2] - Analyst consensus projects Evrysdi sales to reach CHF 2.3 billion ($2.9 billion) by 2030 [2] Group 3: Company Background - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical sector [5] - The company collaborates with various entities, including academic institutions and leading pharmaceutical companies, to fund innovation directly and indirectly [5] - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 20 development-stage candidates [5]

Core Insights - Gilead Sciences has exercised its option to exclusively license Assembly Biosciences' herpes simplex virus helicase-primase inhibitor programs, marking the first advancement under their collaboration [1][2] Licensing Agreement - Gilead entered a 12-year partnership with Assembly Biosciences in 2023 to develop novel antiviral therapies, with Assembly Bio receiving a $35 million payment upon Gilead's exercise of its option [2] - Gilead will obtain exclusive rights to ABI-5366 and ABI-1179, taking full responsibility for their clinical development and commercialization [2] Financial Milestones - Assembly Biosciences is eligible for up to $330 million in regulatory and commercial milestones, along with tiered royalties on net sales [3][7] Product Development - ABI-1179 and ABI-5366 are long-acting helicase-primase inhibitors showing strong antiviral activity and significant reduction in virus-positive lesions in interim data from early-stage studies [8][9] - Over four million people in the U.S. and some European countries suffer from recurrent genital herpes, indicating a substantial market opportunity for these new therapies [9][10] Market Context - No new HSV therapies have been approved in the U.S. or Europe in over 25 years, highlighting the potential impact of ABI-5366 and ABI-1179 if successfully developed [9][10] Gilead's HIV Portfolio - Gilead has a leading HIV franchise, with products like Biktarvy and Descovy driving top-line growth [11] - The recent FDA approval of lenacapavir for HIV prevention enhances Gilead's portfolio, especially as Truvada faces generic competition [12]

Core Insights - Gilead Sciences, Inc. will be participating in the J.P. Morgan Healthcare Conference on January 12, 2026, at 11:15 a.m. Pacific Time [1] Company Overview - Gilead Sciences, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines [1]